Paper
0
Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer
Authors
Alexander Drilon,Geoffrey Oxnard
Daniel Tan,Herbert Loong,Melissa Johnson,Justin Gainor,Caroline McCoach,Oliver Gautschi,Benjamin Besse,Byoung Cho,Nir Peled,Jared Weiss,Yu-Jung Kim,Yuichiro Ohe,Makoto Nishio,Keunchil Park,Jyoti Patel,Takashi Seto,Tomohiro Sakamoto,Ezra Rosen,Manisha Shah,Fabrice Barlési,Philippe Cassier,Lyudmila Bazhenova,Filippo Braud,Elena Garralda,Vamsidhar Velcheti,Miyako Satouchi,Kadoaki Ohashi,Nathan Pennell,Karen Reckamp,Grace Dy,Jürgen Wolf,Benjamin Solomon,Gerald Falchook,Kevin Ebata,M. Nguyen,Binoj Nair,Edward Zhu,Luxi Yang,Xin Huang,Elizabeth Olek,S. Rothenberg,Kōichi Goto
+42 authors
,Vivek SubbiahPublished
Aug 27, 2020
Show more
Save
Tip0
TipSave
Abstract
RET fusions are oncogenic drivers in 1 to 2% of non–small-cell lung cancers (NSCLCs). In patients with RET fusion–positive NSCLC, the efficacy and safety of selective RET inhibition are unknown.
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.